Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


08.01.2024

11 Ann Surg Oncol
3 Anticancer Res
8 BMC Cancer
1 BMJ
3 Breast Cancer
1 Breast Cancer (Dove Med Press)
4 Breast Cancer Res
1 Breast Cancer Res Treat
2 Breast J
1 Cancer
1 Cancer Res
1 Clin Breast Cancer
1 Eur Radiol
1 Histopathology
1 J Clin Oncol
1 J Natl Cancer Inst
2 NPJ Breast Cancer
3 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Surg Oncol

  1. KOBZEVA-HERZOG A, O'Shea T, Young S, Kenzik K, et al
    Breast Cancer Screening and BI-RADS Scoring Trends Before and During the COVID-19 Pandemic in an Academic Safety-Net Hospital.
    Ann Surg Oncol. 2024 Jan 4. doi: 10.1245/s10434-023-14787.
    PubMed         Abstract available

  2. HIGGINS T, Kantor O, Harrison B, Giordano J, et al
    Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
    Ann Surg Oncol. 2023 Dec 31. doi: 10.1245/s10434-023-14835.
    PubMed         Abstract available

  3. CHEN JC, Handley D, Elsaid MI, Plascak JJ, et al
    ASO Visual Abstract: The Implications of Racialized Economic Segregation and Allostatic Load on Mortality in Patients with Breast Cancer.
    Ann Surg Oncol. 2023 Dec 29. doi: 10.1245/s10434-023-14788.
    PubMed        

  4. BHATIA MB, Kisilu N, Kiptoo S, Limenik I, et al
    Breast Health Awareness: Understanding Health-Seeking Behavior in Western Kenya.
    Ann Surg Oncol. 2024;31:1190-1199.
    PubMed         Abstract available

  5. APOSTOLOVA C, Ferroum A, Alhassan B, Prakash I, et al
    ASO Visual Abstract: Surgical Decision Making in Genetically High-Risk Women-Quantifying Postoperative Complications and Long-Term Risks of Supplemental Surgery After Risk-Reducing Mastectomy.
    Ann Surg Oncol. 2024;31:1018-1019.
    PubMed        

  6. MYERS SP, Bayard S, Tadros AB, Sevilimedu V, et al
    ASO Visual Abstract: Examining Race and Patient-Reported Outcomes After Contralateral Prophylactic Mastectomy with Reconstruction.
    Ann Surg Oncol. 2024;31:1023-1024.
    PubMed        

  7. MYERS SP, Bayard S, Tadros AB, Sevilimedu V, et al
    Examining Race and Patient-Reported Outcomes After Contralateral Prophylactic Mastectomy with Reconstruction.
    Ann Surg Oncol. 2024;31:966-973.
    PubMed         Abstract available

  8. HERSH EH, Minami CA, Weiss A, King TA, et al
    Opportunities for De-Escalation of Axillary Surgery in Patients with Ductal Carcinoma in Situ with Microinvasion.
    Ann Surg Oncol. 2024;31:726-728.
    PubMed        

  9. LOHANI KR, Hoskin TL, Day CN, Yasir S, et al
    ASO Author Reflections: Toward Individualized Management of Heterogenous Mixed Invasive Ductolobular Breast Cancers.
    Ann Surg Oncol. 2024;31:1008-1009.
    PubMed         Abstract available

  10. TOKITA HK, Assel M, Simon BA, Lin E, et al
    ASO Visual Abstract: Regional Blocks Benefit Patients Undergoing Bilateral Mastectomy with Immediate Implant-Based Reconstruction, Even After Discharge.
    Ann Surg Oncol. 2024;31:1014-1015.
    PubMed        

  11. KANTOR O, King TA, Jones A, Glass C, et al
    ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS-A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial.
    Ann Surg Oncol. 2024;31:1010-1011.
    PubMed        


    Anticancer Res

  12. CORRADO G, Bove S, Alberghetti B, Fragomeni SM, et al
    Surgical Bedside Electrochemotherapy for Local Control of a Recurrent Phylloid Malignant Breast Tumor: A Case Report.
    Anticancer Res. 2024;44:435-439.
    PubMed         Abstract available

  13. BENZAID I, DE Boisferon MH, Dit Chatel EM, Littlefield BA, et al
    Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models.
    Anticancer Res. 2024;44:61-70.
    PubMed         Abstract available

  14. OZAKI A, Matsuda A, Maemura Y, Tada Y, et al
    Luminal B Breast Cancer Coexpressing p62 and ALDH1A3 Is Less Susceptible to Radiotherapy.
    Anticancer Res. 2024;44:37-47.
    PubMed         Abstract available


    BMC Cancer

  15. XU X, Zhao W, Liu C, Gao Y, et al
    The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:13.
    PubMed         Abstract available

  16. SETIAWAN L, Graef K, Schmolze D, Alem A, et al
    Building pathology capacity in sub-Saharan Africa to improve breast cancer diagnosis and treatment: training laboratory technicians in high-quality manual immunohistochemistry.
    BMC Cancer. 2024;24:32.
    PubMed         Abstract available

  17. HUANG X, Yu Y, Luo S, Fu W, et al
    The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on >/= 1 line of endocrine therapy: systematic review and meta-analysis.
    BMC Cancer. 2024;24:21.
    PubMed         Abstract available

  18. CHOULLI F, Tafenzi HA, Hattimy FE, Choulli MK, et al
    Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study : Mohammed VI University Hospital, Medical Oncology Department, Marrakech, Morocco.
    BMC Cancer. 2024;24:17.
    PubMed         Abstract available

  19. WANG W, Lei W, Fang Z, Jiang R, et al
    Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
    BMC Cancer. 2024;24:1.
    PubMed         Abstract available

  20. ZHAO S, Miao M, Wang Q, Zhao H, et al
    The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
    BMC Cancer. 2024;24:30.
    PubMed         Abstract available

  21. XUE X, Guo L, Guo C, Li L, et al
    Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer.
    BMC Cancer. 2024;24:23.
    PubMed         Abstract available

  22. GHASEMIAN M, Zehtabi M, Dari MAG, Pour FK, et al
    The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers.
    BMC Cancer. 2024;24:4.
    PubMed         Abstract available


    BMJ

  23. SARKAR S
    How patriarchy and conservatism fuel deadly hesitancy among women with breast cancer.
    BMJ. 2024;384:p2563.
    PubMed        


    Breast Cancer

  24. TAIRA N, Kikawa Y, Iwamoto T, Miyoshi Y, et al
    Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
    Breast Cancer. 2024 Jan 4. doi: 10.1007/s12282-023-01537.
    PubMed         Abstract available

  25. HORIMOTO Y
    Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
    Breast Cancer. 2024;31:154.
    PubMed         Abstract available

  26. YOSHIDA M, Yoshimura RI, Notake R, Shinjo H, et al
    Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.
    Breast Cancer. 2024;31:75-83.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  27. ZHU X, Yu J, Ai F, Wang Y, et al
    CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1.
    Breast Cancer (Dove Med Press). 2023;15:967-984.
    PubMed         Abstract available


    Breast Cancer Res

  28. LOPEZ-VELAZCO JI, Manzano S, Otano M, Elorriaga K, et al
    A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2024;26:3.
    PubMed         Abstract available

  29. BRAUNE EB, Geist F, Tang X, Kalari K, et al
    Identification of a Notch transcriptomic signature for breast cancer.
    Breast Cancer Res. 2024;26:4.
    PubMed         Abstract available

  30. TAO J, Xue C, Cao M, Ye J, et al
    Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway.
    Breast Cancer Res. 2024;26:1.
    PubMed         Abstract available

  31. ZIRPOLI GR, Pfeiffer RM, Bertrand KA, Huo D, et al
    Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women.
    Breast Cancer Res. 2024;26:2.
    PubMed         Abstract available


    Breast Cancer Res Treat

  32. ZHU Y, Zerdes I, Matikas A, Cruz IR, et al
    The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
    Breast Cancer Res Treat. 2024 Jan 4. doi: 10.1007/s10549-023-07200.
    PubMed         Abstract available


    Breast J

  33. CARLSON KA, Checka C, Hunt KK, Jung J, et al
    Evaluation of a Surgical Navigation System for Localization and Excision of Nonpalpable Lesions in Breast and Axillary Surgery.
    Breast J. 2023;2023:9993852.
    PubMed         Abstract available

  34. SONG JE, Jang JY, Kang KN, Jung JS, et al
    Multi-MicroRNA Analysis Can Improve the Diagnostic Performance of Mammography in Determining Breast Cancer Risk.
    Breast J. 2023;2023:9117047.
    PubMed         Abstract available


    Cancer

  35. BHATT R, van den Hout A, Antoniou AC, Shah M, et al
    Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors.
    Cancer. 2024 Jan 4. doi: 10.1002/cncr.35183.
    PubMed         Abstract available


    Cancer Res

  36. SOOSAINATHAN A, Iravani M, El-Botty R, Alexander J, et al
    Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Cancer Res. 2024;84:17-25.
    PubMed         Abstract available


    Clin Breast Cancer

  37. GABA AG, Cao L, Renfrew RJ, Witte D, et al
    The Impact of Medicaid Expansion Under the Affordable Care Act on the Gap Between American Indians and Whites in Breast Cancer Management and Prognosis.
    Clin Breast Cancer. 2023 Nov 24:S1526-8209(23)00301.
    PubMed         Abstract available


    Eur Radiol

  38. AL-BAZZAZ H, Janicijevic M, Strand F
    Reader bias in breast cancer screening related to cancer prevalence and artificial intelligence decision support-a reader study.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10514.
    PubMed         Abstract available


    Histopathology

  39. LUI JW, Tsang JY, Li J, Ko CW, et al
    TRPS1 is a promising marker for all subtypes of breast cancer.
    Histopathology. 2024 Jan 3. doi: 10.1111/his.15126.
    PubMed         Abstract available


    J Clin Oncol

  40. BEDROSIAN I, Somerfield MR, Achatz MI, Boughey JC, et al
    Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
    J Clin Oncol. 2024 Jan 4:JCO2302225. doi: 10.1200/JCO.23.02225.
    PubMed         Abstract available


    J Natl Cancer Inst

  41. O'SULLIVAN CC, Ruddy KJ
    Improving our treatment of breast cancer during pregnancy.
    J Natl Cancer Inst. 2023 Dec 29:djad259. doi: 10.1093.
    PubMed        


    NPJ Breast Cancer

  42. CHEN M, Yu S, van der Sluis T, Zwager MC, et al
    cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer.
    NPJ Breast Cancer. 2024;10:1.
    PubMed         Abstract available

  43. GUERRIERO JL, Lin JR, Pastorello RG, Du Z, et al
    Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
    NPJ Breast Cancer. 2024;10:2.
    PubMed         Abstract available


    PLoS One

  44. BUGA A, Harper DG, Sapper TN, Hyde PN, et al
    Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial.
    PLoS One. 2024;19:e0296523.
    PubMed         Abstract available

  45. VAGNINI D, Natalucci V, Moi S, Vallorani L, et al
    Home-based lifestyle intervention for breast cancer survivors: A surprising improvement in the quality of life during the first year of COVID-19 pandemic.
    PLoS One. 2024;19:e0296163.
    PubMed         Abstract available


  46. Retraction: Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer.
    PLoS One. 2023;18:e0296553.
    PubMed        


    Radiology

  47. DU S, Gao S, Wang M, Zhang L, et al
    Multiparametric MRI Radiomics for the Identification of HER2-Low Breast Cancers.
    Radiology. 2024;310:e232092.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.